NOOPEPT (CAPSULES)

Noopept

Noopept (omberacetam; development code GVS-111) is a synthetic N-acylated dipeptide, the ethyl ester of N-phenylacetyl-L-prolylglycine. It was designed in Russia in the 1990s as a peptide analogue of piracetam and first reported in 1996. Unlike the peptides in this collection it is a small, orally stable molecule, supplied here in capsules.

Product Specifications

• Product: Noopept
• Amount: See available options above
• Form: Capsules (dry fill), shipped in a sealed mylar pouch
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed at room temperature (20–25°C), away from heat, moisture and light.
• Ships from: United States, 2-day UPS

Chemical Profile

• Compound class: Synthetic dipeptide derivative (N-phenylacetyl-L-prolylglycine ethyl ester)
• Molecular formula: C₁₇H₂₂N₂O₄
• Molecular weight: 318.4 g/mol
• CAS number: 157115-85-0

What researchers study

Much of the research on Noopept concerns what happens to it after administration. Rat studies identified cyclo-L-prolylglycine, a cyclic dipeptide that also occurs naturally in the brain, as its major metabolite, so Noopept is often described as a prodrug. Lines of investigation include:

• Metabolism and pharmacokinetics: formation of cycloprolylglycine in rat brain and passage across the blood-brain barrier.
• Receptor and neurotrophin signaling: cell studies showing that cycloprolylglycine raises BDNF levels in neuronal cells, with protective effects that depend on AMPA- and TrkB-receptor activation.
• Transcription factors: work linking Noopept to activation of HIF-1, examined through molecular docking and cell assays.
• Neuroprotection models: human cortical neuron cultures under oxidative stress, and rodent models of amyloid-β toxicity and learning tasks.

The literature comes predominantly from the institute where the compound was developed. Animal and cell findings do not establish effects in humans.

Regulatory status

Noopept is registered as a medicine in Russia. It is not approved by the FDA, which regards it as an unapproved drug when marketed for human use. The capsules sold here are a research reagent, not a dietary supplement or approved drug product.

Quality & Documentation

Every batch of Noopept is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). The batch Certificate of Analysis is posted on this page and in our COA Library, so the pouch in your lab can be matched to its report.

Selected literature

• Gudasheva TA, et al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet. 1997;22(3):245-252. PMID 9358206
• Ostrovskaia RU, et al. The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol. 2002;65(5):66-72. PMID 12596521
• Vakhitova YV, et al. Molecular mechanism underlying the action of substituted Pro-Gly dipeptide Noopept. Acta Naturae. 2016;8(1):82-89. PMID 27099787
• Gudasheva TA, et al. Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells. Dokl Biochem Biophys. 2016;469(1):273-276. PMID 27599510
• Zainullina LF, et al. Cognitive enhancer Noopept activates transcription factor HIF-1. Dokl Biochem Biophys. 2020;494(1):256-260. PMID 33119829

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.